Progress and Prospects on Vaccine Development against SARS-CoV-2

• Published in: Vaccines (Basel) Vol. 8; no. 2; p. 153
• Main Authors: Zhang, Jinyong, Zeng, Hao, Gu, Jiang, Li, Haibo, Zheng, Lixin, Zou, Quanming
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29-03-2020; MDPI
• Subjects: adjuvant; animal model; Antigens; Clinical trials; Coronaviridae; Coronaviruses; COVID-19; Deoxyribonucleic acid; DNA; Epidemics; Genomes; Immunoglobulins; Infections; Infectious diseases; Medical research; Middle East respiratory syndrome; Molecular weight; Nanoparticles; Pandemics; Peptides; Pneumonia; Proteins; Public health; Review; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Signal transduction; Transgenic animals; vaccine; Vaccine development; Vaccines; Viral diseases; Viruses; China; SARS-CoV-2; vaccine; animal model; adjuvant
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines8020153

In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.